Benchmark Existing Models & Interrogate Practical Applications of NAMs to Accelerate More Predictive In Vitro, In Vivo, & Computational Models
With nearly 90% of drug candidates failing in the clinic, and one-third of those failures driven by safety, toxicology has reached a critical inflection point. Traditional preclinical models are no longer sufficient to predict human risk, costing biopharma millions in late-stage attrition and stalled pipelines.
In 2026, toxicology enters a new era. The FDA’s landmark 2025 roadmap to reduce reliance on animal testing has accelerated adoption of New Approach Methodologies (NAMs), including in vitro, microphysiological, and computational models. At the same time, CROs and technology developers are rapidly releasing new platforms, but uncertainty remains around predictivity, validation standards, and regulatory positioning.
This meeting is the only industry-led forum dedicated to benchmarking what truly works in predictive toxicology. Designed by toxicologists for toxicologists, it brings together pharma, biotech, regulators, and model developers to critically evaluate in vivo, in vitro, and in silico strategies, share real IND case studies, and define fit-for-purpose model selection across modalities.
If you are responsible for de-risking first-in-human decisions, advancing NAM adoption, or improving safety translation, this is the essential forum to separate innovation from hype and build toxicology strategies that stand up clinically and regulatorily.
Testimonials From Hanson Wade’s 13th Tumor Models Boston Summit 2025
Many of the presentations were very interesting and gave raise to discussion! The vendors were very well selected, and the networking opportunities were good.
Astellas Pharma
The meeting is very well organized and met all my expectations and beyond!
Novartis
It was an incredibly enriching experience. What made it most enjoyable was the opportunity to engage directly with scientists, clinicians, and industry experts who are driving innovation in the field. The depth and breadth of the presentations.
Medicenna Therapeutics
Explore the Full Event Guide
- Hear from 50+ toxicology leaders from pharma, biotech, FDA & global consortia sharing real-world IND and model validation experience
- Featuring 2 pre-conference workshops deep-diving into regulatory strategy, NAMs validation, and translational drug development decision-making
- Discover end-to-end coverage of NAMs from in vitro & MPS to in silico and virtual control groups, benchmarked against in vivo data
- High-value networking with decision-makers through roundtables, panels, and structured networking sessions
- Learn about case-driven sessions across modalities, including ADCs, bispecifics, cell therapy, radio-conjugates, and small molecules
Attending Companies Include
Explore Related Events
Explore the Scientific Agenda
Dive into a highly practical program benchmarking in vivo, in vitro, and in silico toxicology models, with real-world case studies on NAM validation, regulatory strategy, dose selection, and human-relevant translation.
Partner With Toxicology Leaders
Position your solutions at the center of industry decision-making as pharma and biotech actively evaluate next-generation CRO services, NAM platforms, AI tools, and translational models to reduce risk and accelerate IND success.
Join Toxicology Decision-Makers
Connect with investigative, translational, preclinical, and regulatory toxicologists from the top biopharma companies through focused workshops, panels, and networking designed to spark meaningful scientific and commercial conversations.